Allarity Therapeutics (ALLR) Depreciation & Amortization (CF) (2020 - 2025)

Allarity Therapeutics (ALLR) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $12000.0 in Q2 2025.

• Quarterly Depreciation & Amortization (CF) rose 1100.0% year-over-year to $12000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $12000.0 (down 33.33% YoY) and the FY2024 annual result came in at $9000.0, down 75.68% from the prior year.
• Depreciation & Amortization (CF) improved to $12000.0 in Q2 2025, from $11000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $56000.0 in Q1 2021 to a low of -$3000.0 in Q2 2021.
• A 5-year average of $13055.6 and a median of $9500.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) tumbled 88.89% — and 2025, when it soared 1100.0%.
• Tracing ALLR's Depreciation & Amortization (CF) over 5 years: stood at $16000.0 in 2021, then tumbled by 87.5% to $2000.0 in 2022, then surged by 350.0% to $9000.0 in 2023, then plunged by 88.89% to $1000.0 in 2024, then soared by 1100.0% to $12000.0 in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $12000.0 (Q2 2025), $11000.0 (Q1 2025), and $1000.0 (Q4 2024), per Business Quant data.